An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

David J. Adelstein, Yi Li, George L. Adams, Henry Wagner, Julie A. Kish, John F. Ensley, David E. Schuller, Arlene A. Forastiere

Research output: Contribution to journalArticle

1126 Citations (Scopus)

Abstract

Purpose: The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer. Patients and Methods: Eligible patients were randomly assigned between arm A (the control), single daily fractionated radiation (70 Gy at 2 Gy/d); arm B, identical radiation therapy with concurrent bolus cisplatin, given on days 1, 22, and 43; and arm C, a split course of single daily fractionated radiation and three cycles of concurrent infusional fluorouracil and bolus cisplatin chemotherapy, 30 Gy given with the first cycle and 30 to 40 Gy given with the third cycle. Surgical resection was encouraged if possible after the second chemotherapy cycle on arm C and, if necessary, as salvage therapy on all three treatment arms. Survival data were compared between each experimental arm and the control arm using a one-sided log-rank test. Results: Between 1992 and 1999, 295 patients were entered on this trial. This did not meet the accrual goal of 362 patients and resulted in premature study closure. Grade 3 or worse toxicity occurred in 52% of patients enrolled in arm A, compared with 89% enrolled in arm B (P < .0001) and 77% enrolled in arm C (P < .001). With a median follow-up of 41 months, the 3-year projected overall survival for patients enrolled in arm A is 23%, compared with 37% for arm B (P = .014) and 27% for arm C (P = not significant). Conclusion: The addition of concurrent high-dose, single agent cisplatin to conventional single daily fractionated radiation significantly improves survival, although it also increases toxicity. The loss of efficacy resulting from split course radiation was not offset by either multiagent chemotherapy or the possibility of midcourse surgery.

Original languageEnglish (US)
Pages (from-to)92-98
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Squamous Cell Neoplasms
Chemoradiotherapy
Head and Neck Neoplasms
Appointments and Schedules
Arm
Radiotherapy
Radiation
Cisplatin
Drug Therapy
Survival
Radiation Dosage
Salvage Therapy
Fluorouracil
Neck
Head

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Adelstein, David J. ; Li, Yi ; Adams, George L. ; Wagner, Henry ; Kish, Julie A. ; Ensley, John F. ; Schuller, David E. ; Forastiere, Arlene A. / An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 1. pp. 92-98.
@article{37a25479e3424ce0b99d3537fb431aa5,
title = "An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer",
abstract = "Purpose: The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer. Patients and Methods: Eligible patients were randomly assigned between arm A (the control), single daily fractionated radiation (70 Gy at 2 Gy/d); arm B, identical radiation therapy with concurrent bolus cisplatin, given on days 1, 22, and 43; and arm C, a split course of single daily fractionated radiation and three cycles of concurrent infusional fluorouracil and bolus cisplatin chemotherapy, 30 Gy given with the first cycle and 30 to 40 Gy given with the third cycle. Surgical resection was encouraged if possible after the second chemotherapy cycle on arm C and, if necessary, as salvage therapy on all three treatment arms. Survival data were compared between each experimental arm and the control arm using a one-sided log-rank test. Results: Between 1992 and 1999, 295 patients were entered on this trial. This did not meet the accrual goal of 362 patients and resulted in premature study closure. Grade 3 or worse toxicity occurred in 52{\%} of patients enrolled in arm A, compared with 89{\%} enrolled in arm B (P < .0001) and 77{\%} enrolled in arm C (P < .001). With a median follow-up of 41 months, the 3-year projected overall survival for patients enrolled in arm A is 23{\%}, compared with 37{\%} for arm B (P = .014) and 27{\%} for arm C (P = not significant). Conclusion: The addition of concurrent high-dose, single agent cisplatin to conventional single daily fractionated radiation significantly improves survival, although it also increases toxicity. The loss of efficacy resulting from split course radiation was not offset by either multiagent chemotherapy or the possibility of midcourse surgery.",
author = "Adelstein, {David J.} and Yi Li and Adams, {George L.} and Henry Wagner and Kish, {Julie A.} and Ensley, {John F.} and Schuller, {David E.} and Forastiere, {Arlene A.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1200/JCO.2003.01.008",
language = "English (US)",
volume = "21",
pages = "92--98",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. / Adelstein, David J.; Li, Yi; Adams, George L.; Wagner, Henry; Kish, Julie A.; Ensley, John F.; Schuller, David E.; Forastiere, Arlene A.

In: Journal of Clinical Oncology, Vol. 21, No. 1, 01.01.2003, p. 92-98.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer

AU - Adelstein, David J.

AU - Li, Yi

AU - Adams, George L.

AU - Wagner, Henry

AU - Kish, Julie A.

AU - Ensley, John F.

AU - Schuller, David E.

AU - Forastiere, Arlene A.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Purpose: The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer. Patients and Methods: Eligible patients were randomly assigned between arm A (the control), single daily fractionated radiation (70 Gy at 2 Gy/d); arm B, identical radiation therapy with concurrent bolus cisplatin, given on days 1, 22, and 43; and arm C, a split course of single daily fractionated radiation and three cycles of concurrent infusional fluorouracil and bolus cisplatin chemotherapy, 30 Gy given with the first cycle and 30 to 40 Gy given with the third cycle. Surgical resection was encouraged if possible after the second chemotherapy cycle on arm C and, if necessary, as salvage therapy on all three treatment arms. Survival data were compared between each experimental arm and the control arm using a one-sided log-rank test. Results: Between 1992 and 1999, 295 patients were entered on this trial. This did not meet the accrual goal of 362 patients and resulted in premature study closure. Grade 3 or worse toxicity occurred in 52% of patients enrolled in arm A, compared with 89% enrolled in arm B (P < .0001) and 77% enrolled in arm C (P < .001). With a median follow-up of 41 months, the 3-year projected overall survival for patients enrolled in arm A is 23%, compared with 37% for arm B (P = .014) and 27% for arm C (P = not significant). Conclusion: The addition of concurrent high-dose, single agent cisplatin to conventional single daily fractionated radiation significantly improves survival, although it also increases toxicity. The loss of efficacy resulting from split course radiation was not offset by either multiagent chemotherapy or the possibility of midcourse surgery.

AB - Purpose: The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer. Patients and Methods: Eligible patients were randomly assigned between arm A (the control), single daily fractionated radiation (70 Gy at 2 Gy/d); arm B, identical radiation therapy with concurrent bolus cisplatin, given on days 1, 22, and 43; and arm C, a split course of single daily fractionated radiation and three cycles of concurrent infusional fluorouracil and bolus cisplatin chemotherapy, 30 Gy given with the first cycle and 30 to 40 Gy given with the third cycle. Surgical resection was encouraged if possible after the second chemotherapy cycle on arm C and, if necessary, as salvage therapy on all three treatment arms. Survival data were compared between each experimental arm and the control arm using a one-sided log-rank test. Results: Between 1992 and 1999, 295 patients were entered on this trial. This did not meet the accrual goal of 362 patients and resulted in premature study closure. Grade 3 or worse toxicity occurred in 52% of patients enrolled in arm A, compared with 89% enrolled in arm B (P < .0001) and 77% enrolled in arm C (P < .001). With a median follow-up of 41 months, the 3-year projected overall survival for patients enrolled in arm A is 23%, compared with 37% for arm B (P = .014) and 27% for arm C (P = not significant). Conclusion: The addition of concurrent high-dose, single agent cisplatin to conventional single daily fractionated radiation significantly improves survival, although it also increases toxicity. The loss of efficacy resulting from split course radiation was not offset by either multiagent chemotherapy or the possibility of midcourse surgery.

UR - http://www.scopus.com/inward/record.url?scp=0037208591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037208591&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.01.008

DO - 10.1200/JCO.2003.01.008

M3 - Article

C2 - 12506176

AN - SCOPUS:0037208591

VL - 21

SP - 92

EP - 98

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -